HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 435.17 Million USD | -16.79% |
| 2022 | 522.99 Million USD | 22.71% |
| 2021 | 426.21 Million USD | 80.5% |
| 2020 | 236.12 Million USD | 24.44% |
| 2019 | 189.75 Million USD | 17.86% |
| 2018 | 161 Million USD | 35.53% |
| 2017 | 118.8 Million USD | 11.46% |
| 2016 | 106.58 Million USD | 38.07% |
| 2015 | 77.19 Million USD | 187.34% |
| 2014 | 26.86 Million USD | 16.08% |
| 2013 | 23.14 Million USD | -75.73% |
| 2012 | 95.35 Million USD | 9.38% |
| 2011 | 87.17 Million USD | 5.72% |
| 2010 | 82.46 Million USD | 15.32% |
| 2009 | 71.5 Million USD | 10.05% |
| 2008 | 64.98 Million USD | 37.21% |
| 2007 | 47.35 Million USD | 37.26% |
| 2006 | 34.5 Million USD | 18.33% |
| 2005 | 29.15 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 76.53 Million USD | 135.8% |
| 2024 Q2 | 76.53 Million USD | 0.0% |
| 2023 Q1 | 3.74 Million USD | -84.5% |
| 2023 FY | 435.17 Million USD | -16.79% |
| 2023 Q4 | 32.45 Million USD | -12.09% |
| 2023 Q3 | 36.91 Million USD | 885.18% |
| 2023 Q2 | 3.74 Million USD | 0.0% |
| 2022 Q2 | 24.83 Million USD | 0.0% |
| 2022 Q3 | 24.17 Million USD | -2.64% |
| 2022 FY | 522.99 Million USD | 22.71% |
| 2022 Q4 | 24.17 Million USD | 0.0% |
| 2022 Q1 | 24.83 Million USD | -6.08% |
| 2021 Q4 | 26.44 Million USD | 0.0% |
| 2021 Q3 | 26.44 Million USD | -73.03% |
| 2021 FY | 426.21 Million USD | 80.5% |
| 2021 Q2 | 98.03 Million USD | 22.82% |
| 2021 Q1 | 79.81 Million USD | 833.3% |
| 2020 Q3 | 8.55 Million USD | -85.4% |
| 2020 FY | 236.12 Million USD | 24.44% |
| 2020 Q1 | 42.77 Million USD | 3128.08% |
| 2020 Q2 | 58.58 Million USD | 36.97% |
| 2020 Q4 | 8.55 Million USD | 0.0% |
| 2019 Q2 | 48.35 Million USD | 2.31% |
| 2019 Q1 | 47.26 Million USD | 863.15% |
| 2019 FY | 189.75 Million USD | 17.86% |
| 2019 Q4 | 1.32 Million USD | -91.12% |
| 2019 Q3 | 14.91 Million USD | -69.15% |
| 2018 Q3 | 26.12 Million USD | -40.2% |
| 2018 FY | 161 Million USD | 35.53% |
| 2018 Q2 | 43.69 Million USD | 8.41% |
| 2018 Q1 | 40.3 Million USD | 708.14% |
| 2018 Q4 | 4.9 Million USD | -81.22% |
| 2017 FY | 118.8 Million USD | 11.46% |
| 2017 Q4 | 4.98 Million USD | 0.0% |
| 2017 Q1 | 232.99 Thousand USD | -98.13% |
| 2017 Q3 | 4.98 Million USD | 2040.35% |
| 2017 Q2 | 232.99 Thousand USD | 0.0% |
| 2016 FY | 106.58 Million USD | 38.07% |
| 2016 Q4 | 12.44 Million USD | 0.0% |
| 2016 Q3 | 12.44 Million USD | 1002.84% |
| 2016 Q2 | 1.12 Million USD | 0.0% |
| 2016 Q1 | 1.12 Million USD | -95.44% |
| 2015 Q1 | 4.16 Million USD | 163.53% |
| 2015 FY | 77.19 Million USD | 187.34% |
| 2015 Q4 | 24.74 Million USD | -14.68% |
| 2015 Q3 | 29 Million USD | 596.36% |
| 2015 Q2 | 4.16 Million USD | 0.0% |
| 2014 Q2 | 681 Thousand USD | 0.0% |
| 2014 Q1 | 681 Thousand USD | -98.0% |
| 2014 Q4 | -6.55 Million USD | -132.54% |
| 2014 FY | 26.86 Million USD | 16.08% |
| 2014 Q3 | 20.15 Million USD | 2859.32% |
| 2013 Q1 | 1.06 Million USD | 0.05% |
| 2013 Q2 | 1.06 Million USD | 0.0% |
| 2013 Q3 | 5.49 Million USD | 415.52% |
| 2013 Q4 | 33.99 Million USD | 518.33% |
| 2013 FY | 23.14 Million USD | -75.73% |
| 2012 FY | 95.35 Million USD | 9.38% |
| 2012 Q4 | 1.06 Million USD | 0.0% |
| 2012 Q3 | 1.06 Million USD | 0.0% |
| 2011 FY | 87.17 Million USD | 5.72% |
| 2010 FY | 82.46 Million USD | 15.32% |
| 2009 FY | 71.5 Million USD | 10.05% |
| 2008 FY | 64.98 Million USD | 37.21% |
| 2007 FY | 47.35 Million USD | 37.26% |
| 2006 FY | 34.5 Million USD | 18.33% |
| 2005 FY | 29.15 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -1681.76% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 88.728% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -1124.919% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -22.955% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -2444.597% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 26.365% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 64.59% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 13.563% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -100.886% |
| SSY Group Limited | 1.98 Billion HKD | 78.03% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -165.553% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -51.445% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 98.518% |